Ischemia Reperfusion Injury - Pipeline Review, H1 2016

Published: Feb, 2016 | Pages: 200 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Ischemia Reperfusion Injury - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Ischemia Reperfusion Injury - Pipeline Review, H1 2016', provides an overview of the Ischemia Reperfusion Injury pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Ischemia Reperfusion Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ischemia Reperfusion Injury and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Ischemia Reperfusion Injury
- The report reviews pipeline therapeutics for Ischemia Reperfusion Injury by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Ischemia Reperfusion Injury therapeutics and enlists all their major and minor projects
- The report assesses Ischemia Reperfusion Injury therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Ischemia Reperfusion Injury

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Ischemia Reperfusion Injury
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Ischemia Reperfusion Injury pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Ischemia Reperfusion Injury Overview 8
Therapeutics Development 9
Pipeline Products for Ischemia Reperfusion Injury - Overview 9
Pipeline Products for Ischemia Reperfusion Injury - Comparative Analysis 10
Ischemia Reperfusion Injury - Therapeutics under Development by Companies 11
Ischemia Reperfusion Injury - Therapeutics under Investigation by Universities/Institutes 14
Ischemia Reperfusion Injury - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Ischemia Reperfusion Injury - Products under Development by Companies 19
Ischemia Reperfusion Injury - Products under Investigation by Universities/Institutes 22
Ischemia Reperfusion Injury - Companies Involved in Therapeutics Development 24
Amyndas Pharmaceuticals LLC 24
Angion Biomedica Corp. 25
Antipodean Pharmaceuticals, Inc. 26
Bayer AG 27
Biomedica Management Corporation 28
Bolder Biotechnology, Inc. 29
Curatis Pharma GmbH 30
Ensemble Therapeutics Corporation 31
Erimos Pharmaceuticals, LLC 32
Gilead Sciences, Inc. 33
Ischemix, Inc. 34
Kowa Company, Ltd. 35
LG Life Science LTD. 36
Magnus Life Science 37
NeuroVive Pharmaceutical AB 38
Nyken B.V. 39
Omeros Corporation 40
Opsona Therapeutics Limited 41
Orexo AB 42
Pharming Group N.V. 43
PledPharma AB 44
Prolong Pharmaceuticals 45
Proteo, Inc. 46
Prothix BV 47
Stealth BioTherapeutics Inc. 48
Zealand Pharma A/S 49
Ischemia Reperfusion Injury - Therapeutics Assessment 50
Assessment by Monotherapy Products 50
Assessment by Target 51
Assessment by Mechanism of Action 55
Assessment by Route of Administration 58
Assessment by Molecule Type 60
Drug Profiles 62
AER-271 - Drug Profile 62
AM/AMBP-1 - Drug Profile 63
ANV-6L15 - Drug Profile 66
APP-103 - Drug Profile 67
BAY-606583 - Drug Profile 68
BB-3 - Drug Profile 69
BBT-059 - Drug Profile 73
bucillamine - Drug Profile 74
C1 esterase inhibitor (human) - Drug Profile 75
CMX-2043 - Drug Profile 80
CRX-526 - Drug Profile 82
Curaglutide - Drug Profile 83
danegaptide - Drug Profile 84
Des-Asp Angiotensin 1 - Drug Profile 86
Drugs to Inhibit ADAM17 for Ischemia Reperfusion Injury - Drug Profile 87
EP-80317 - Drug Profile 88
GS-459679 - Drug Profile 89
KN-93 - Drug Profile 90
LH-021 - Drug Profile 92
mangafodipir trisodium - Drug Profile 93
MG-53 - Drug Profile 94
mirococept - Drug Profile 96
MitoQ - Drug Profile 98
Monoclonal Antibody for Ischemia Reperfusion Injury - Drug Profile 100
Monoclonal Antibody to Inhibit CD47 for Cardiovascular Disease, Kidney Transplantation and Oncology - Drug Profile 101
Monoclonal Antibody to Inhibit IL-16 for Renal Ischemia Reperfusion Injury - Drug Profile 103
MTP-131 - Drug Profile 104
NBD Peptide - Drug Profile 106
NecX - Drug Profile 108
Neutrolide - Drug Profile 109
NP-202 - Drug Profile 111
NVP-019 - Drug Profile 113
NYK-1112 - Drug Profile 114
Oligonucleotide for Oncology and Cardiovascular - Drug Profile 115
OMS-721 - Drug Profile 116
OPN-305 - Drug Profile 118
PAC-G31P - Drug Profile 120
PIN-201601 - Drug Profile 122
pitavastatin NP - Drug Profile 123
PMC-6 - Drug Profile 124
PRO-02 - Drug Profile 125
R-190 - Drug Profile 126
Recombinant Peptide to Activate FPR2 for Ischemia Reperfusion Injury and Myocardial Ischemia - Drug Profile 128
Recombinant Protein for Sepsis, Inflammatory Bowel Disease, Acute Kidney Injury, Acute Radiation Syndrome and Ischemic Organ Injury - Drug Profile 129
Recombinant Protein Slit2 to Agonize Robo1 for Ischemia Reperfusion Injury and Thrombosis - Drug Profile 131
Recombinant Protein to Inhibit CXCL for Pancreatitis, Cardiovascular and Immunology - Drug Profile 132
Recombinant Proteins for Ischemia Reperfusion Injury and Hypoxia - Drug Profile 133
Recombinant Proteins to Agonize PTCH1 for Ischemia Reperfusion Injury - Drug Profile 134
Recombinat Protein to Antagonize Interleukin-1 Receptor for Cardiomyopathy and Ischemia Reperfusion Injury - Drug Profile 135
Sanguinate - Drug Profile 136
Small Molecule for Reperfusion Injury and Heart Attack - Drug Profile 138
Small Molecule to Agonize Opioid Delta for Reperfusion Injury - Drug Profile 139
Small Molecule to Inhibit Arginase-1 and Arginase-2 for Myocardial Ischemia and Ischemia Reperfusion Injury - Drug Profile 140
Small Molecules for Ischemia Reperfusion Injury - Drug Profile 141
Small Molecules for Ischemia Reperfusion Injury - Drug Profile 142
Small Molecules for Ischemia Reperfusion Injury - Drug Profile 143
Small Molecules for Ischemia Reperfusion Injury and Inflammation - Drug Profile 144
Small Molecules to Activate SGK-1 for Ischemic Reperfusion Injury - Drug Profile 145
Small Molecules to Inhibit Cyclophilin D for Reperfusion Injury and Alzheimer's Disease - Drug Profile 146
Small Molecules to Inhibit PDE5 for Cardiovascular Disease - Drug Profile 147
Synthetic Peptides for Ischemia Reperfusion Injury - Drug Profile 148
Synthetic Peptides for Oncology, Immunology and Cardiovascular Disorders - Drug Profile 149
terameprocol - Drug Profile 150
tiomolibdate diammonium - Drug Profile 152
tiprelestat - Drug Profile 153
TMS-007 - Drug Profile 156
UCF-101 - Drug Profile 157
UWA-TAT - Drug Profile 158
Ischemia Reperfusion Injury - Recent Pipeline Updates 159
Ischemia Reperfusion Injury - Dormant Projects 178
Ischemia Reperfusion Injury - Discontinued Products 184
Ischemia Reperfusion Injury - Product Development Milestones 185
Featured News & Press Releases 185
Appendix 194
Methodology 194
Coverage 194
Secondary Research 194
Primary Research 194
Expert Panel Validation 194
Contact Us 194
Disclaimer 195

List of Tables
Number of Products under Development for Ischemia Reperfusion Injury, H1 2016 14
Number of Products under Development for Ischemia Reperfusion Injury - Comparative Analysis, H1 2016 15
Number of Products under Development by Companies, H1 2016 16
Number of Products under Development by Companies, H1 2016 (Contd..1) 17
Number of Products under Development by Companies, H1 2016 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H1 2016 19
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 20
Comparative Analysis by Late Stage Development, H1 2016 21
Comparative Analysis by Clinical Stage Development, H1 2016 22
Comparative Analysis by Early Stage Development, H1 2016 23
Products under Development by Companies, H1 2016 24
Products under Development by Companies, H1 2016 (Contd..1) 25
Products under Development by Companies, H1 2016 (Contd..2) 26
Products under Investigation by Universities/Institutes, H1 2016 27
Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 28
Ischemia Reperfusion Injury - Pipeline by Amyndas Pharmaceuticals LLC, H1 2016 29
Ischemia Reperfusion Injury - Pipeline by Angion Biomedica Corp., H1 2016 30
Ischemia Reperfusion Injury - Pipeline by Antipodean Pharmaceuticals, Inc., H1 2016 31
Ischemia Reperfusion Injury - Pipeline by Bayer AG, H1 2016 32
Ischemia Reperfusion Injury - Pipeline by Biomedica Management Corporation, H1 2016 33
Ischemia Reperfusion Injury - Pipeline by Bolder Biotechnology, Inc., H1 2016 34
Ischemia Reperfusion Injury - Pipeline by Curatis Pharma GmbH, H1 2016 35
Ischemia Reperfusion Injury - Pipeline by Ensemble Therapeutics Corporation, H1 2016 36
Ischemia Reperfusion Injury - Pipeline by Erimos Pharmaceuticals, LLC, H1 2016 37
Ischemia Reperfusion Injury - Pipeline by Gilead Sciences, Inc., H1 2016 38
Ischemia Reperfusion Injury - Pipeline by Ischemix, Inc., H1 2016 39
Ischemia Reperfusion Injury - Pipeline by Kowa Company, Ltd., H1 2016 40
Ischemia Reperfusion Injury - Pipeline by LG Life Science LTD., H1 2016 41
Ischemia Reperfusion Injury - Pipeline by Magnus Life Science, H1 2016 42
Ischemia Reperfusion Injury - Pipeline by NeuroVive Pharmaceutical AB, H1 2016 43
Ischemia Reperfusion Injury - Pipeline by Nyken B.V., H1 2016 44
Ischemia Reperfusion Injury - Pipeline by Omeros Corporation, H1 2016 45
Ischemia Reperfusion Injury - Pipeline by Opsona Therapeutics Limited, H1 2016 46
Ischemia Reperfusion Injury - Pipeline by Orexo AB, H1 2016 47
Ischemia Reperfusion Injury - Pipeline by Pharming Group N.V., H1 2016 48
Ischemia Reperfusion Injury - Pipeline by PledPharma AB, H1 2016 49
Ischemia Reperfusion Injury - Pipeline by Prolong Pharmaceuticals, H1 2016 50
Ischemia Reperfusion Injury - Pipeline by Proteo, Inc., H1 2016 51
Ischemia Reperfusion Injury - Pipeline by Prothix BV, H1 2016 52
Ischemia Reperfusion Injury - Pipeline by Stealth BioTherapeutics Inc., H1 2016 53
Ischemia Reperfusion Injury - Pipeline by Zealand Pharma A/S, H1 2016 54
Assessment by Monotherapy Products, H1 2016 55
Number of Products by Stage and Target, H1 2016 57
Number of Products by Stage and Mechanism of Action, H1 2016 61
Number of Products by Stage and Route of Administration, H1 2016 64
Number of Products by Stage and Molecule Type, H1 2016 66
Ischemia Reperfusion Injury Therapeutics - Recent Pipeline Updates, H1 2016 164
Ischemia Reperfusion Injury - Dormant Projects, H1 2016 183
Ischemia Reperfusion Injury - Dormant Projects (Contd..1), H1 2016 184
Ischemia Reperfusion Injury - Dormant Projects (Contd..2), H1 2016 185
Ischemia Reperfusion Injury - Dormant Projects (Contd..3), H1 2016 186
Ischemia Reperfusion Injury - Dormant Projects (Contd..4), H1 2016 187
Ischemia Reperfusion Injury - Dormant Projects (Contd..5), H1 2016 188
Ischemia Reperfusion Injury - Discontinued Products, H1 2016 189